Prevalence of Sarcopenia and Its Geriatric Features

January 25, 2018 updated by: Murielle Surquin, Brugmann University Hospital

The goal of this study is to determine the prevalence of sarcopenia in a geriatric hospital ward.

Sarcopenia is defined by a loss of muscle mass, loss of muscle strength and loss of muscle quality. It is a geriatric syndrome that, to this date, is not systematically tracked in clinical practice.

In order to detect sarcopenia, the investigators will use the operational definition proposed by the European Working Group (EWGSOP) involving the measure of three parameters, namely the speed of walking, the muscle strength and the measurement of the muscular mass.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

834

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
      • Brussels, Belgium, 1020
        • CHU Brugmann

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Each patient over 65 years admitted to the unit 83 of the Geriatric Department, CHU Brugmann Hospital, from 10/01/2016 till 30/03/2017 undergoes a comprehensive geriatric assessment at the end of its hospitalisation stay. The screening for sarcopenia is part of this geriatric assessment.

Description

Inclusion Criteria:

  • To be admitted in the unit 83 of the Geriatric Departement of the CHU Brugmann hospital, from 10/01/2016 till 30/03/2017.

Exclusion Criteria:

  • Patients unable to consent or without representatives
  • Patients unable to perform the hand- grip test, the walk test or measurement of the body components by DEXA
  • Patients in severe pain
  • Bedridden patients
  • Patients for which a clear therapeutic abstention has been established
  • Language barriere that cannot be overcome
  • Patients unable to walk without the help of a third person

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Geriatric ward population
Every patient aged over 65 admitted in the unit 83 of the Geriatry Department, CHU Brugmann Hospital, undergoes a global geriatric evaluation at the end of its hospitalisation stay, including sarcopenia detection.
Other: Sarcopenia detection

The assessment of sarcopenia is performed according to the recommendations of the EWGSOP (European Working Group on Sarcopenia in Older people). Three measurements are made:

  • Muscle mass measurement by dual energy X-ray absorptiometry (DEXA).
  • Walking speed measurement
  • Hand grip test

A diagnosis of sarcopenia is established if the walking speed is inferior to 0.8 m/sec, the muscular strength is low and the muscular mass is low.

Data regarding the geriatric characteristics of this sarcopenic population will be collected.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of sarcopenia
Time Frame: From 10/01/2016 till 30/03/2017 (up to 15 months)
Sarcopenia detection will be performed at the end of each hospitalization stay in unit 83 of the CHU Brugmann Hospital (Geriatry Department)
From 10/01/2016 till 30/03/2017 (up to 15 months)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of hospitalized patients unable to perform the sarcopenia detection test
Time Frame: From 10/01/2016 till 30/03/2017 (up to 15 months)
Systematic retrospective review of patients hospitalised in the geriatric ward of the CHU Brugmann hospital during the length of the study, in order to determine the percentage of patients that could not, because of one of more exclusion criteria, perform the sarcopenia detection test.
From 10/01/2016 till 30/03/2017 (up to 15 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Brugmann University Hospital

Investigators

  • Principal Investigator: Robin Barré, MD, CHU Brugmann
  • Principal Investigator: Florence Benoit, MD, CHU Brugmann
  • Principal Investigator: Marie Claessens, MD, CHU Brugmann

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 1, 2016

Primary Completion (ACTUAL)

January 18, 2018

Study Completion (ACTUAL)

January 18, 2018

Study Registration Dates

First Submitted

January 19, 2016

First Submitted That Met QC Criteria

January 22, 2016

First Posted (ESTIMATE)

January 27, 2016

Study Record Updates

Last Update Posted (ACTUAL)

January 26, 2018

Last Update Submitted That Met QC Criteria

January 25, 2018

Last Verified

January 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CHUB-sarcopenia

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sarcopenia

Clinical Trials on Sarcopenia detection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe